These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Lock-and-Kill Anticancer Photoactivated Chemotherapy Agent van Geest EP; Götzfried SK; Klein DM; Salitra N; Popal S; Husiev Y; Van der Griend CJ; Zhou X; Siegler MA; Schneider GF; Bonnet S Photochem Photobiol; 2023 Mar; 99(2):777-786. PubMed ID: 36315051 [TBL] [Abstract][Full Text] [Related]
3. To cage or to be caged? The cytotoxic species in ruthenium-based photoactivated chemotherapy is not always the metal. Cuello-Garibo JA; Meijer MS; Bonnet S Chem Commun (Camb); 2017 Jun; 53(50):6768-6771. PubMed ID: 28597879 [TBL] [Abstract][Full Text] [Related]
4. Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy. Lu Y; Zhu D; Le Q; Wang Y; Wang W Nanoscale; 2022 Nov; 14(44):16339-16375. PubMed ID: 36341705 [TBL] [Abstract][Full Text] [Related]
6. Light-activated ruthenium (II)-bicalutamide prodrugs for prostate cancer. Zhao J; Liu N; Sun S; Gou S; Wang X; Wang Z; Li X; Zhang W J Inorg Biochem; 2019 Jul; 196():110684. PubMed ID: 31054419 [TBL] [Abstract][Full Text] [Related]
7. Lightening up Ruthenium Complexes to Fight Cancer? Mari C; Gasser G Chimia (Aarau); 2015; 69(4):176-81. PubMed ID: 26668934 [TBL] [Abstract][Full Text] [Related]
8. Photo-induced DNA cleavage and cytotoxicity of a ruthenium(II) arene anticancer complex. Brabec V; Pracharova J; Stepankova J; Sadler PJ; Kasparkova J J Inorg Biochem; 2016 Jul; 160():149-55. PubMed ID: 26778426 [TBL] [Abstract][Full Text] [Related]
9. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Bergamo A; Sava G Dalton Trans; 2011 Aug; 40(31):7817-23. PubMed ID: 21629963 [TBL] [Abstract][Full Text] [Related]
10. A Red-Light-Activated Ruthenium-Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells. Lameijer LN; Ernst D; Hopkins SL; Meijer MS; Askes SHC; Le Dévédec SE; Bonnet S Angew Chem Int Ed Engl; 2017 Sep; 56(38):11549-11553. PubMed ID: 28666065 [TBL] [Abstract][Full Text] [Related]
11. Red-Light-Responsive Metallopolymer Nanocarriers with Conjugated and Encapsulated Drugs for Phototherapy Against Multidrug-Resistant Tumors. Chen M; Gong N; Sun W; Han J; Liu Y; Zhang S; Zheng A; Butt HJ; Liang XJ; Wu S Small; 2022 Jul; 18(27):e2201672. PubMed ID: 35665442 [TBL] [Abstract][Full Text] [Related]
12. A nuclear permeable Ru(ii)-based photoactivated chemotherapeutic agent towards a series of cancer cells: in vitro and in vivo studies. Tian N; Feng Y; Sun W; Lu J; Lu S; Yao Y; Li C; Wang X; Zhou Q Dalton Trans; 2019 May; 48(19):6492-6500. PubMed ID: 30994660 [TBL] [Abstract][Full Text] [Related]
16. Strong Influence of Ancillary Ligands Containing Benzothiazole or Benzimidazole Rings on Cytotoxicity and Photoactivation of Ru(II) Arene Complexes. Lari M; Martínez-Alonso M; Busto N; Manzano BR; Rodríguez AM; Acuña MI; Domínguez F; Albasanz JL; Leal JM; Espino G; García B Inorg Chem; 2018 Nov; 57(22):14322-14336. PubMed ID: 30379535 [TBL] [Abstract][Full Text] [Related]
17. Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy. Reeßing F; Szymanski W Curr Med Chem; 2017; 24(42):4905-4950. PubMed ID: 27601187 [TBL] [Abstract][Full Text] [Related]
18. BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds. Hongthong K; Ratanaphan A Curr Cancer Drug Targets; 2016; 16(7):606-17. PubMed ID: 26845433 [TBL] [Abstract][Full Text] [Related]
19. Photocontrolled DNA binding of a receptor-targeted organometallic ruthenium(II) complex. Barragán F; López-Senín P; Salassa L; Betanzos-Lara S; Habtemariam A; Moreno V; Sadler PJ; Marchán V J Am Chem Soc; 2011 Sep; 133(35):14098-108. PubMed ID: 21797210 [TBL] [Abstract][Full Text] [Related]
20. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Brabec V; Nováková O Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]